Comparison of Efficacy Between S-1 and Capecitabine/Fluorouracil on Advanced Colorectal Cancer: A Meta-analysis

• Main Authors: ZHAO Rongchang, YU Wenyan, FENG Yuxin, ZHANG Wanli, ZHU Chunrong
• Format: Article
• Language: zho
• Published: Magazine House of Cancer Research on Prevention and Treatment 2019-12-01
• Series: Zhongliu Fangzhi Yanjiu
• Subjects: colorectal cancer; s-1; capecitabine; fluorouracil; meta-analysis
• Online Access: http://html.rhhz.net/ZLFZYJ/html/8578.2019.19.0138.htm
• ISSN: 1000-8578; 1000-8578

Objective To conduct a meta-analysis on the data of S-1 and capecitabine or fluorouracil in the treatment of advanced colorectal cancer, to demonstrate the feasibility of S-1 replacing capecitabine or fluorouracil. Methods We searched published literature in the PubMed, Cochrane Library, Embase and CNKI databases, and searched for controlled trials at the Clinical Trials Center (<a href="https://www.clinicaltrials.gov/" target="_blank">https://www.clinicaltrials.gov/</a>). The data extraction and quality evaluation were conducted according to Cochrane Handbook 5.1.0, and RevMan 5.3 software was used for the meta-analysis of relevant case-control studies. Results The data of 3462 patients from 11 randomized controlled trials were included. Compared with the capecitabine/fluorouracil regimen, OS was improved in the S-1 treatment group, but there was no statistically significant difference in PFS, DCR or ORR. The incidence of diarrhea, renal insufficiency and hand-foot syndrome in the S-1 group was lower than that in the control group. But the incidence of platelet reduction in the S-1 group was higher than that in the control group at a reasonable contrast dose. Conclusion S-1 has a certain therapeutic advantage after replacing capecitabine or fluorouracil in conventional chemotherapy on advanced colorectal cancer.